<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04757532</url>
  </required_header>
  <id_info>
    <org_study_id>IMIMFTCL/ESPAMA</org_study_id>
    <nct_id>NCT04757532</nct_id>
  </id_info>
  <brief_title>Study of Exposure to Substances Prohibited by the World Anti-Doping Agency in Healthy Volunteers.</brief_title>
  <acronym>ESPAMA</acronym>
  <official_title>Study of Exposure to Substances Prohibited by the World Anti-Doping Agency in Healthy Volunteers.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Parc de Salut Mar</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Parc de Salut Mar</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background:&#xD;
&#xD;
      The use of stimulants such as bupropion, enzyme inhibitors such as anastrozole, androgens&#xD;
      such as testosterone, antigonadotropins such as danazol, and diuretics such as chlorthalidone&#xD;
      have been reported in urine drug testing programs for a wide variety of applications,&#xD;
      including anti-doping tests in sport. These substances are subject to screening studies by&#xD;
      the World Anti-Doping Agency (WADA). Anastrozole, chlorthalidone, testosterone and danazol&#xD;
      are included on the WADA list of prohibited substances, while bupropion is included in the&#xD;
      2020 follow-up schedule of substances.&#xD;
&#xD;
      This study aims to characterize the urinary excretion patterns of these substances following&#xD;
      the administration of a single dose of each drug at a recommended therapeutic dose.&#xD;
&#xD;
      Hypothesis:&#xD;
&#xD;
      The administration of bupropion, anastrozole, testosterone, danazol or chlorthalidone in&#xD;
      healthy subjects allows the generation of detectable concentrations of the drug in urine&#xD;
      using the liquid chromatography technique coupled to mass spectrometry (LC-MS). Positive&#xD;
      urine samples will enable to identify analytical strategies for doping control.&#xD;
&#xD;
      Objectives:&#xD;
&#xD;
      Primary objective: To measure the concentrations of various drugs (anastrozole, bupropion,&#xD;
      chlorthalidone, danazol and testosterone) and their metabolites in urine for anti-doping&#xD;
      control samples. The detection of new metabolites excreted in urine for longer periods of&#xD;
      time than conventional metabolites will improve the ability to detect the abuse of anabolic&#xD;
      steroids in sport.&#xD;
&#xD;
      Secondary objective: To assess safety and tolerability of the drugs used.&#xD;
&#xD;
      Methods:&#xD;
&#xD;
      Phase I, unicentric, open, non-randomized, non-controlled clinical trial, with 5 parallel&#xD;
      treatment conditions (anastrozole, bupropion, chlorthalidone, danazol and testosterone)&#xD;
      administered in a single dose to male healthy volunteers (total n=11).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 3, 2020</start_date>
  <completion_date type="Actual">March 10, 2021</completion_date>
  <primary_completion_date type="Actual">March 10, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Single-center, non-randomized, unblinded, uncontrolled clinical trial in healthy male volunteers, at a single dose of the five study drugs (bupropion, anastrozole, testosterone cyclopentylpropionate, danazol and chlorthalidone).</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Urine concentration of bupropion metabolites</measure>
    <time_frame>0-4 h (hours), 4-8h, 8-12h, 12-24h, 24-48h and 48-72h post-administration</time_frame>
    <description>Concentration of bupropion metabolites in each fraction of urine samples</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Urine concentration of anastrozole metabolites</measure>
    <time_frame>0-24 h (hours), 24-48h, 48-72h, 72-96h, 96-120h, 120-144h and 144-168h post-administration</time_frame>
    <description>Concentration of anastrozole metabolites in each fraction of urine samples</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Urine concentration of testosterone metabolites</measure>
    <time_frame>0-20 days post-administration (24-hour fractions)</time_frame>
    <description>Concentration of testosterone metabolites in each fraction of urine samples</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Urine concentration of danazol metabolites</measure>
    <time_frame>0-4 h (hours), 4-8h, 8-12h, 12-24h, 24-36h and 36-48h post-administration</time_frame>
    <description>Concentration of danazol metabolites in each fraction of urine samples</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Urine concentration of chlorthalidone metabolites</measure>
    <time_frame>0-12 h (hours), 12-24h, 24-48h and 48-72h post-administration</time_frame>
    <description>Concentration of chlorthalidone metabolites in each fraction of urine samples</description>
  </primary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">9</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>Bupropion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects receive a single-dose treatment. Urine samples will be collected until 3 days after administration in 6 fractions: 0-4h, 4-8h, 8-12h, 12-24h, 24-48h, 48-72h post-administration.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Anastrozole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects receive a single-dose treatment. Urine samples will be collected until 7 days after administration in 7 fractions: 0-24h, 24-48h, 48-72h, 72-96h, 96-120h, 120-144h, 144-168h post-administration.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Testosterone cyclopentylpropionate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects receive a single-dose treatment. Urine samples will be collected until 20 days after administration in 20 fractions: first urine of the day, every day.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Danazol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects receive a single-dose treatment. Urine samples will be collected until 2 days after administration in 6 fractions: 0-4h, 4-8h, 8-12h, 12-24h, 24-36h, 36-48h post-administration.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Chlorthalidone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects receive a single-dose treatment. Urine samples will be collected until 3 days after administration in 4 fractions: 0-12h, 12-24h, 24-48h y 48-72h post-administration.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bupropion</intervention_name>
    <description>300 mg of bupropion hydrochloride (1 tablet) administered orally in a single dose.</description>
    <arm_group_label>Bupropion</arm_group_label>
    <other_name>Elontril®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anastrozole</intervention_name>
    <description>1 mg of anastrozole (1 tablet) administered orally in a single dose.</description>
    <arm_group_label>Anastrozole</arm_group_label>
    <other_name>Anastrozol Mylan®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Testosterone cyclopentylpropionate</intervention_name>
    <description>100 mg of testosterone cyclopentylpropionate (equivalent to 70 mg of testosterone) administered via intramuscular injection in a single dose (2 mL).</description>
    <arm_group_label>Testosterone cyclopentylpropionate</arm_group_label>
    <other_name>Testex prolongatum®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Danazol</intervention_name>
    <description>200 mg of danazol (1 capsule) administered orally in a single dose.</description>
    <arm_group_label>Danazol</arm_group_label>
    <other_name>Danatrol®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chlorthalidone</intervention_name>
    <description>50 mg of chlorthalidone (1 tablet) administered orally in a single dose.</description>
    <arm_group_label>Chlorthalidone</arm_group_label>
    <other_name>Higrotona®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male volunteers aged between 18 and 50 years.&#xD;
&#xD;
          -  Able to understand and accept the trial procedures and able to sign an informed&#xD;
             consent.&#xD;
&#xD;
          -  History and physical examination that demonstrate not presenting organic or&#xD;
             psychiatric disorders.&#xD;
&#xD;
          -  ECG, blood and urine tests performed before the experimental session within normal&#xD;
             limits. Minor or occasional variations of these limits will be allowed if, in the&#xD;
             opinion of the Principal Investigator and taking into account the state of science,&#xD;
             they have no clinical significance, do not pose a risk to the subject and do not&#xD;
             interfere in the product evaluation. These variations and their non-relevance will be&#xD;
             specifically justified in writing.&#xD;
&#xD;
          -  Body mass index (weight/height^2) between 19 and 27 kg/m2 and weight between 50 and&#xD;
             100 kg. BMI of 27-28 kg/m2 may be included according to Principal Investigator's&#xD;
             criteria.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Failure to meet inclusion criteria.&#xD;
&#xD;
          -  History of allergy, idiosyncrasy, hypersensitivity or adverse reactions to the active&#xD;
             substance or any of the excipients. Lactose intolerance. Serious adverse reactions to&#xD;
             any drug.&#xD;
&#xD;
          -  Contraindications to treatment with study drugs (according to the respective summary&#xD;
             of product characteristics, SmPC). Especially history or presence of breast cancer,&#xD;
             liver cancer, and suspected or confirmed prostate carcinoma.&#xD;
&#xD;
          -  History or current presence of prostate syndrome symptoms: frequent urination (both&#xD;
             day and night), difficulty in starting urination, weak or discontinuous urinary&#xD;
             stream, feeling of incomplete bladder emptying, or benign prostatic hyperplasia&#xD;
             diagnosis.&#xD;
&#xD;
          -  Levels of prostate specific antigen (PSA) out of normal range for subject's age, in&#xD;
             those receiving anastrozole, testosterone or danazol.&#xD;
&#xD;
          -  Clinical background or evidence of gastrointestinal, hepatic, renal disorder or others&#xD;
             that may involve an alteration of the absorption, distribution, metabolism or&#xD;
             excretion of the drug.&#xD;
&#xD;
          -  Clinical background or evidence of psychiatric disorders, alcoholism, drug abuse or&#xD;
             habitual consumption of psychoactive drugs.&#xD;
&#xD;
          -  Having participated in another clinical trial with medication in the three months&#xD;
             prior to the start of the study.&#xD;
&#xD;
          -  Having suffered some organic disease or major surgery in the six months prior to the&#xD;
             start of the study.&#xD;
&#xD;
          -  Clinical background or evidence of cardiovascular, respiratory, renal, hepatic,&#xD;
             endocrine, gastrointestinal, hematological, neurological, dermatological or other&#xD;
             acute or chronic diseases that, in the opinion of the Principal Investigator or the&#xD;
             collaborators designated by him/her, may pose a risk to the subjects or may interfere&#xD;
             with the objectives of the study. Especially history of venous thrombosis or&#xD;
             thromboembolic disorders, thrombophilic alteration, edema, hypercalcemia,&#xD;
             polycythemia, nephrosis, liver disease with altered liver function tests and&#xD;
             porphyria.&#xD;
&#xD;
          -  Having taken medication regularly in the month prior to the study sessions, including&#xD;
             vitamins, herbal remedies or dietary supplements. Treatment with a single dose of&#xD;
             symptomatic medication in the week prior to the study sessions will not be a reason&#xD;
             for exclusion if it is assumed that the drug has been completely eliminated on the day&#xD;
             of the experimental session.&#xD;
&#xD;
          -  Smokers of more than 20 cigarettes a day in the 3 months before the study.&#xD;
&#xD;
          -  Consumption of more than 40 g of alcohol daily.&#xD;
&#xD;
          -  Consumers of more than 5 coffees, teas, cola drinks, or other stimulant drinks or with&#xD;
             xanthines daily in the 3 months prior to the study start.&#xD;
&#xD;
          -  Being unable to understand the nature, consequences of the trial and the procedures&#xD;
             that are asked to follow.&#xD;
&#xD;
          -  Positive serology for hepatitis B, C or HIV.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ana M Aldea Perona, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>IMIM (Hospital del Mar Medical Research Institute)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>IMIM (Hospital del Mar Medical Research Institute)</name>
      <address>
        <city>Barcelona</city>
        <zip>08003</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>February 14, 2021</study_first_submitted>
  <study_first_submitted_qc>February 16, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 17, 2021</study_first_posted>
  <last_update_submitted>April 23, 2021</last_update_submitted>
  <last_update_submitted_qc>April 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Anti-doping control</keyword>
  <keyword>Bupropion</keyword>
  <keyword>Anastrozole</keyword>
  <keyword>Danazol</keyword>
  <keyword>Chlorthalidone</keyword>
  <keyword>Testosterone</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methyltestosterone</mesh_term>
    <mesh_term>Anastrozole</mesh_term>
    <mesh_term>Chlorthalidone</mesh_term>
    <mesh_term>Bupropion</mesh_term>
    <mesh_term>Testosterone</mesh_term>
    <mesh_term>Testosterone undecanoate</mesh_term>
    <mesh_term>Testosterone enanthate</mesh_term>
    <mesh_term>Testosterone 17 beta-cypionate</mesh_term>
    <mesh_term>Danazol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

